Role of p16 in the pathogenesis of Langerhans cell histiocytosis.
BACKGROUND
It has been hypothesized that genetic alteration at the cellular level may have a significant effect on cellular mechanisms controlling the proliferation and apoptosis of Langerhans cells (LCs).


METHODS
We examined whether p16 protein expression can be used to predict the outcome of Langerhans cell histiocytosis (LCH). Archival paraffin blocks from children diagnosed with LCH and followed at the Asan Medical Center and Chungnam National University Hospital between March 1998 and February 2008 were studied.


RESULTS
Slides were stained with p16 antibody and evaluated semi-quantitatively using the following scale: negative, no staining; ±, weakly positive; 1+, staining similar to lymphocytes surrounding the LCs; 2+, stronger staining than lymphocytes; 3+, much stronger staining than lymphocytes. Negative and ± groups were assigned to a lower expression group (LEG) and the 1+, 2+, and 3+ groups were assigned to a higher expression group (HEG). The median age of the 51 patients (24 girls, 27 boys) was 49 (range, 0.6-178) months, and LCH was diagnosed based on CD1a positivity. p16 protein was expressed to varying degrees in all but one specimen. There was a greater tendency toward multisystem disease, risk organ involvement, and relapse in the HEG than in the LEG.


CONCLUSIONS
The p16 protein may have a significant effect on cellular mechanisms controlling the proliferation and apoptosis of LCs, and thus may influence the clinical outcome and prognosis of LCH.
Department of Pediatrics, College of Medicine, Hanyang University Hospital, Seoul, Korea.
Sun-Young
SY
Kim
Hyoung-Jin
HJ
Kim
Hee-Jin
HJ
Kim
Mee-Rim
MR
Park
Kyung-Nam
KN
Koh
Ho-Joon
HJ
Im
Chul-Hoon
CH
Lee
Jong-Jin
JJ
Seo
Leuk Res. 2000 Jan;24(1):39-46
10634644
Curr Opin Pediatr. 2008 Feb;20(1):23-9
18197035
Pediatr Dev Pathol. 1998 May-Jun;1(3):210-5
10463280
Am J Hematol. 2005 Dec;80(4):282-7
16315255
Eur J Cardiothorac Surg. 2003 Feb;23(2):221-8
12559346
Int Rev Cytol. 2006;254:1-43
17147996
Pediatr Dermatol. 2008 May-Jun;25(3):291-5
18577030
Clin Cancer Res. 2008 Nov 1;14(21):7151-7
18981015
J Pediatr Hematol Oncol. 2002 Dec;24(9):733-6
12468914
Hematol Oncol Clin North Am. 1998 Apr;12(2):407-16
9561909
N Engl J Med. 1986 Aug 21;315(8):475-9
3488502
Mol Hum Reprod. 1998 Dec;4(12):1099-109
9872359
Leukemia. 1998 Jun;12(6):845-59
9639410
J Pediatr Hematol Oncol. 2002 Dec;24(9):727-32
12468913
Pediatr Blood Cancer. 2008 Feb;50(2):304-7
17455317
Histopathology. 2003 Feb;42(2):186-93
12558751
Hum Pathol. 2007 Dec;38(12):1849-57
17900658
Oncogene. 2000 Mar 16;19(12):1589-95
10734319
Curr Opin Oncol. 1995 Nov;7(6):541-6
8547403
Oncol Rep. 2008 Nov;20(5):1137-42
18949413
World J Gastroenterol. 2010 Jul 28;16(28):3553-60
20653064
Pediatr Dev Pathol. 2007 Jan-Feb;10(1):18-24
17378622
Exp Gerontol. 2000 May;35(3):317-29
10832053
Clin Cancer Res. 2001 Jun;7(6):1765-72
11410518
Pediatr Blood Cancer. 2007 May;48(5):555-60
16652350